Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

40.67 +0.02 (+0.06%)
Streaming Delayed Price Updated: 12:03 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
20 21 Next >
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Apellis Pharmaceuticals, Inc. (APLS) Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
APLS DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS
WHY: New York, NY - (NewMediaWire) - August 13, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between... 
Via TheNewswire.com
Topics Lawsuit
News headline image
Where Apellis Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS
WHY: New York, NY - (NewMediaWire) - August 13, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between... 
Via NewMediaWire
Topics Lawsuit
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS
WHY: New York, NY - (NewMediaWire) - August 12, 2023 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of... 
Via TheNewswire.com
Topics Lawsuit
News headline image
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eos, Apellis, Party City, and Hayward and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Amyris, Inc. (NASDAQ: AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy. 
Via Benzinga
Topics Bankruptcy
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Consolidated Water, Spectrum Brands, Arco Platform, Semler Scientific And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Apellis Pharmaceuticals, Inc. (APLS) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Apellis Pharmaceuticals, Inc. (APLS) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Apellis Pharmaceuticals, Inc. (APLS) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Apellis Pharmaceuticals, Inc. (APLS) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Apellis Pharmaceuticals, Inc. Class Action
From Robbins LLP
Via Business Wire
News headline image
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
APELLIS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Apellis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
ROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – APLS
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin ↗
The company is already under scrutiny after reports of side effects tied to Syfovre. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
News headline image
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $750,000 to Contact the Firm
Via ACCESSWIRE
News headline image
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - APLS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
APELLIS PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - APLS
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Apellis Pharmaceuticals, Inc. (APLS)
From Robbins LLP
Via Business Wire
News headline image
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - APLS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023 ↗
 
Via Benzinga
News headline image
APLS Investor Alert: Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Announce the Filing of a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.